Toronto, ON (PRWEB) June 20, 2023 The Global Alzheimer s Platform Foundation (GAP) is delighted to announce a collaborative, free webinar focusing on the
Broad participation at this year's congress highlights Prothena's leadership in advancing next generation treatments for Alzheimer's and Parkinson's disease Oral presentation on PRX012, Prothena's
Predicting when new drugs come to market in the United States has never been an exact science, but several drugs that could be approved in 2023 could have a significant impact on health for millions of people.
Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did. The results could mean a rare victory in a field filled with failed experiments to find an effective treatment for the disease.